Erika M. Mosesón

Kinase Domain Mutants of Bcr-Abl Exhibit Altered Transformation Potency, Kinase Activity, and Substrate Utilization, Irrespective of Sensitivity to Imatinib

Ian J. Griswold, Mary MacPartlin, Thomas G.P. Bumm et al. · Molecular and Cellular Biology · 2006 · 199 citations · Full text

Medicine, Molecular Biology, Oncology +13

Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML

Thomas O’Hare, Roy M. Pollock, Eric P. Stoffregen et al. · Blood · 2004 · 199 citations · Full text

Medicine, Medicinal Chemistry, Oncology +8

In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl–positive cell lines

Paul La Rosée, Kara Johnson, Amie S. Corbin et al. · Blood · 2003 · 103 citations · Full text

Medicine, Oncology, Pharmacology +8

An Official American Thoracic Society Research Statement: Implementation Science in Pulmonary, Critical Care, and Sleep Medicine

Curtis H. Weiss, Jerry A. Krishnan, David H. Au et al. · American Journal of Respiratory and Critical Care Medicine · 2016 · 76 citations · Full text

Public Health, Health Policy, Evidence-based Practice +11

Patient and Clinician Characteristics Associated with Adherence. A Cohort Study of Veterans with Incidental Pulmonary Nodules

Erika M. Mosesón, Renda Soylemez Wiener, Sara E. Golden et al. · Annals of the American Thoracic Society · 2016 · 52 citations

Social Sciences, Health Behavior, Radiology +16